You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD123-CD33 cCAR

Showing 1 - 25 of 5,178
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CD123-CD33 cCAR T cells)

Unknown status
  • Hematologic Malignancy
  • +4 more
  • CD123-CD33 cCAR T cells
  • Chengdu, China
  • +1 more
Nov 8, 2019

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia Recurrent
  • CD123-CAR-NK cells
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

Acute Myeloid Leukemia Trial in Valencia (AFM28)

Recruiting
  • Acute Myeloid Leukemia
  • Valencia, Spain
    Hospital Universitari i Politècnic La Fe
Apr 5, 2023

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome Trial (VIP943)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • (no location specified)
Sep 5, 2023

Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Anti-CD33 CAR T-cells
  • Lymphodepletion Therapy
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Acute Myeloid Leukemia Trial in Fuzhou (CLL1/+CD33 CAR-T)

Not yet recruiting
  • Acute Myeloid Leukemia
  • CLL1/+CD33 CAR-T
  • Fuzhou, Fujian, China
    Fujian Provincial Children's Hospital
Jul 10, 2023

Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CLL1-CD33 cCAR T cells)

Recruiting
  • Hematologic Malignancy
  • +4 more
  • CLL1-CD33 cCAR T cells
  • Chengdu, China
  • +1 more
May 17, 2021

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

AML, B-ALL, T-ALL Trial in Memphis (CD123-CAR T, Cyclophosphamide, Fludarabine)

Recruiting
  • AML
  • +4 more
  • CD123-CAR T
  • +4 more
  • Memphis, Tennessee
  • +1 more
May 10, 2022

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies Trial in Langfang (anti-CD33 CAR T cells)

Not yet recruiting
  • Relapsed and/or Refractory Acute Myeloid Leukemia
  • High Risk Hematologic Malignancies
  • anti-CD33 CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Jun 30, 2022

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

AML Trial in Hangzhou (CD33 CAR-T)

Not yet recruiting
  • AML
  • CD33 CAR-T
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Jul 21, 2022

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

AML Trial in Beijing (IM23)

Completed
  • AML
  • Beijing, China
    Xian Lu
Jan 18, 2023

AML, Childhood Trial in United States (CD33*CD3 BsAb)

Active, not recruiting
  • AML, Childhood
  • CD33*CD3 BsAb
  • Birmingham, Alabama
  • +12 more
Jan 12, 2023

AML, Adult Trial in Hangzhou (QN-023a, Cyclophosphamid, Fludarabine)

Recruiting
  • AML, Adult
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Dec 29, 2022

Leukemia, Myeloid, Acute Trial in United States (VCAR33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • VCAR33
  • La Jolla, California
  • +9 more
Aug 14, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • SC-DARIC33
  • Seattle, Washington
    Seattle Children's Hospital
Sep 6, 2022